Alwide Plus China Post-market Clinical Investigation

NCT07304427 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2025-12-26

No results posted yet for this study

Summary

This is a prospective, single-arm, multi-center, post-market registry study conducted in China. The purpose is to evaluate the safety and effectiveness of the AlwideTM Plus balloon catheter for pre-dilatation of the aortic valve during TAVR in the real-world setting.

Conditions

  • Severe Aortic Stenosis
  • Transcatheter Aortic Valve Replacemen

Sponsors & Collaborators

  • Shanghai MicroPort CardioFlow Medtech Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-03
Primary Completion
2025-10-11
Completion
2025-11-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07304427 on ClinicalTrials.gov